medigraphic.com

2019, Number 1

<< Back Next >>

Rev Hematol Mex 2019; 20 (1)

Induction chemotherapy with standard-dose cytarabine, daunorubicin and etoposide (7+3+7) versus high-dose cytarabine and daunorubicin in young patients with newly diagnosed acute myeloid leukemia

Valencia-Rocha UR, Demichelis-Gómez R, López-Rosas A, Crespo-Solís E

Language: English
References: 22
Page: 18-27
PDF size: 489.32 Kb.


ABSTRACT

Objective: To compared two more intensive induction regimens than 7+3: 7+3+ etoposide (7+3+7) versus high-dose cytarabine and daunorubicine (HiDAC-D) in patients with acute myeloid leukemia.
Material and Method: A comparative study of 18-55 years old patients treated at National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, from November 2010 to November 2016. Induction regimens used in this study included 7+3+7 (cytarabine 100 mg/m2/day on days 1-7, daunorubicin 45 mg/m2/day on days 1-3 and etoposide 75 mg/m2/day on days 1-7), and HiDAC-D (cytarabine 3000 mg/m2/ day on days 1-3 and daunorubicin 45 mg/m /day on days 1-2).
Results: There were included 40 patients. In the 7+3+7 group, CR (complete remission) was achieved in 76.2% of patients, while in the HiDAC-D treatment group it was 89.4% (17/19; p = 0.44). The group of patients who received the 7+3+7 regimen had a median overall survival (OS) of 17.2 months, while the group that received HiDAC-D had a median OS of 18.9 months (p = 0.620). Unfavorable risk patients treated with the 7+3+7 presented a median OS of 8.8 months versus 5 months for the HiDAC-D treatment group (p = 0.037).
Conclusion: Both induction regimens increased CR rates with one or two cycles without increasing mortality in patients with AML less than 55 years of age in comparison with our historical cohort with 7+3.


REFERENCES

  1. Tallman MS, Gillilan DG, Rowe JM. Drug therapy for acute myeloid leukemia Blood. 2005 Aug 15;106(4):1154-63

  2. Ferrara F, Schiffer CA. Acute myeloid leukemia in adults. Lancet 2013 Feb 9;381(9865):484-95

  3. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015 Sep 17;373(12):1136-52.

  4. Saultz J, Garzon R. Acute myeloid leukemia: A Concise Review. J Clin Med 2016 Mar 5;5(3).

  5. Yates JW, Wallace HR, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acutenonlymphocytic leukemia. Cancer Chemother Rep 1973;57:485.

  6. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990 Jan 1;75(1):27-32.

  7. Willemze R, Sucio S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014 Jan 20;32(3):219-28.

  8. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008. Rev Invest Clin 2010;62(2):100-108.

  9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues, 2008.

  10. NCCN Clinical Practice Guidelines in Oncology version 3.2017-June 6.2017.

  11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003 Dec 15;21(24):4642-9.

  12. Byun JM, Kim YJ, Yoon HJ, et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study. Ann Hematol 2016 Aug;95(8):1223-32.

  13. Slovak ML1, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000 Dec 15;96(13):4075-83.

  14. Byrd JC, Mrózek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002 Dec 15;100(13):4325-36.

  15. Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998 Jan;28(3-4):315-27.

  16. Bishop JF, Lowethal R, Joshua D, Matthews JP, Wolf MM, Cooper IA. Etoposide in leukemia. Cancer 1991 Jan 1;67(1 Suppl):285-91.

  17. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996 Mar 1;87(5):1710-7.

  18. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011 Mar 17;364(11):1027-36.

  19. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009 Sep 24;361(13):1249-59.

  20. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011 Oct 6;118(14):3832-41.

  21. Su L, Zhu X, Gao S, Li W, Liu X, Tan Y. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials. J Chemother 2016 Apr;28(2):123-8.

  22. Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014 Feb 1;32(4):288-96.




2020     |     www.medigraphic.com